Genetics and epigenetics of sporadic thyroid cancer.
Thyroid carcinoma is the most common endocrine malignancy, and although the disease generally has an excellent prognosis, therapeutic options are limited for patients not cured by surgery and radioiodine. Thyroid carcinomas commonly contain one of a small number of recurrent genetic mutations. The identification and study of these mutations has led to a deeper understanding of the pathophysiology of this disease and is providing new approaches to diagnosis and therapy. Papillary thyroid carcinomas usually contain an activating mutation in the RAS cascade, most commonly in BRAF and less commonly in RAS itself or through gene fusions that activate RET. A chromosomal translocation that results in production of a PAX8-PPARG fusion protein is found in follicular carcinomas. Anaplastic carcinomas may contain some of the above changes as well as additional mutations. Therapies that are targeted to these mutations are being used in patient care and clinical trials.
Department of Internal Medicine, Division of Metabolism, Endocrinology and Diabetes, University of Michigan, Ann Arbor, MI, USA. Electronic address: vudang@umich.edu.
Dang
D
Vu-Phan
Department of Internal Medicine, Division of Metabolism, Endocrinology and Diabetes, University of Michigan, Ann Arbor, MI, USA. Electronic address: rkoenig@umich.edu.
Ronald J
RJ
Koenig
D000818:Animals; D044127:Epigenesis, Genetic; D006801:Humans; D051379:Mice; D009154:Mutation / Q000235:genetics; D009363:Neoplasm Proteins / Q000235:genetics / Q000378:metabolism; D013964:Thyroid Neoplasms / Q000235:genetics*
D009363:Neoplasm Proteins
Anaplastic; BRAF; Follicular; PAX8-PPARG; Papillary; RAS